Rex Yannis, MD
Ophthalmic Plastic and Reconstructive Surgery · Chattanooga, TNNPI 1417007691
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $16,670 of the $19,448 with a category attached, or 85.7%. Amgen accounts for 92.7% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2022 at $14,522 and has fallen 98.6% since, to $205 in 2025.
Across 107 payments — averaging $181.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$18K
- Merz North America, Inc.$438
- Mallinckrodt Hospital Products Inc.$378
- AbbVie$144
- E.r. Squibb & Sons, L.L.C.$60
- Alcon$57
- plus $335 from 11 others
What the payments were for
- Speaking & faculty fees$16,67086%
- Travel & lodging$1501%
- Food & beverage$2,41812%
- Education$1911%
- Gifts$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 62 | $18,036 |
| Merz North America, Inc. | 7 | $438 |
| Mallinckrodt Hospital Products Inc. | 12 | $378 |
| AbbVie(2 entities) | 7 | $144 |
| E.r. Squibb & Sons, L.L.C. | 1 | $60 |
| Alcon | 2 | $57 |
| Mallinckrodt Enterprises LLC | 2 | $54 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $49 |
| ANI Pharmaceuticals, Inc. | 2 | $45 |
| Tarsus Pharmaceuticals, Inc. | 2 | $37 |
| Revance Therapeutics, Inc. | 1 | $31 |
| Galderma Laboratories, L.p. | 2 | $28 |
| Biotissue Holdings Inc. | 1 | $22 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Sun Pharmaceutical Industries Inc. | 1 | $18 |
| Dompe US, Inc. | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few ophthalmic plastic and reconstructive surgery providers in Tennesseeto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 15 | $9,848 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 73 | $3,112 |
| ErythromycinErythromycin Base | 192 | $1,904 |
| Bacitracin-PolymyxinBacitracin/Polymyxin B Sulfate | 32 | $333 |
| Ondansetron OdtOndansetron | 71 | $109 |
Paid to pharmacies, not to this prescriber.
Other ophthalmic plastic and reconstructive surgery in Chattanooga
- Andrew MeadorNashville$94K
- Andrew AnzeljcKnoxville$13K
- Stanley PaceKnoxville$1K
- Michelle NguyenFranklin$645
- Trey PegramClarksville$583
- Ralph WesleyNashville$270
- Kimberly KlippensteinNashville$212
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.